Compare GPRK & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GPRK | IMMP |
|---|---|---|
| Founded | 2002 | 1987 |
| Country | Colombia | Australia |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 397.8M | 410.7M |
| IPO Year | 2009 | 2012 |
| Metric | GPRK | IMMP |
|---|---|---|
| Price | $8.44 | $2.76 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 1 |
| Target Price | $8.50 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 615.3K | 161.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.39% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $382.75 |
| Revenue Next Year | $23.25 | N/A |
| P/E Ratio | $12.70 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.66 | $1.32 |
| 52 Week High | $9.09 | $3.53 |
| Indicator | GPRK | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 50.16 | 49.22 |
| Support Level | $7.74 | $2.74 |
| Resistance Level | $8.58 | $3.24 |
| Average True Range (ATR) | 0.35 | 0.13 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 27.27 | 53.22 |
GeoPark Ltd is a Latin American oil and gas exploration and production company with assets in Colombia, Ecuador, Chile, Brazil, and Argentina. The company generates revenue from the sale of crude oil, condensate, and natural gas, net of value-added tax and discounts related to the sale and overriding royalties due to the ex-owners of oil and gas properties where the royalty arrangements represent a retained working interest in the property.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.